SANGUINE CORP. (SGNC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim B who wrote (754)	6/15/1998 6:24:00 PM
From: Hyrulean King	Read Replies (1) of 5402

Jim B: I had a long discussion w/ Dr Drees as to the amount of financing needed and the testing/marketing timeplan of pher-02. Industry averages is 200+mil for testing and development from beginning to end - then marketing fees. The fact is that this product has already undergone 20 years of testing and will only need a fraction of that amount. Again, this product has been in development from 1978. At that time, full product development cost co's 100+mill. Read the press release. Funding is done. Batelle will begin testing shortly. Do you think a co the size and reputation of Batelle would sign up for with a company if they didn't have confidence in the product or company. Dr Drees and Batelle have estimated 95-98% success on pher-02. FDA approval (since this will be approval on a 2nd generation improved product will be easier than the first time it was approved. Average approval time on a 1st gen product is 10+years. The company has estimated 2 1/2 since it is 2nd gen. *One key factor is that there is patent pending in the process, and most likely this product will be gobbled up at or before the product is deemed 'FDA Approvable' before that time is even up. chief

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next